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Aim of database: The Danish Lung Cancer Registry (DLCR) was established by the Danish 
Lung Cancer Group. The primary and first goal of the DLCR was to improve survival and the 
overall clinical management of Danish lung cancer patients.
Study population: All Danish primary lung cancer patients since 2000 are included into the reg-
istry and the database today contains information on more than 50,000 cases of lung cancer.
Main variables: The database contains information on patient characteristics such as age, sex, 
diagnostic procedures, histology, tumor stage, lung function, performance, comorbidities, type 
of surgery, and/or oncological treatment and complications. Since November 2013, DLCR data 
on Patient -Reported Outcome Measures is also included.
Descriptive data: Results are primarily reported as quality indicators, which are published 
online monthly, and in an annual report where the results are commented for local, regional, 
and national audits. Indicator results are supported by descriptive reports with details on diag-
nostics and treatment.
Conclusion: DLCR has since its creation been used to improve the quality of treatment of lung 
cancer in Denmark and it is increasingly used as a source for research regarding lung cancer in 
Denmark and in comparisons with other countries.
Keywords: lung cancer, histology, tumor stage, lung function, performance, comorbidities, 
diagnostic procedures, type of surgery, oncological treatment, treatment complications
Aim of database
The Danish Lung Cancer Registry (DLCR) was established by the Danish Lung Cancer 
Group (DLCG). The primary goal of DLCG and later of the DLCR was to improve 
survival and the clinical management of Danish lung cancer patients. A secondary aim 
has been to produce a platform for lung cancer research. DLCG was established in 1991 
and representatives from medical specialties working with lung cancer were invited to 
participate. Several published papers indicated that the survival of lung cancer patients 
in Denmark was inferior to international standards and that no improvement in the rela-
tive 5-year survival had been observed for several years.1–3 It was the general perception 
among experts that the only way to reduce the number of deaths from lung cancer was to 
intensify the public campaigns against smoking.4 In 1990, more than 90 departments took 
part in diagnostics and treatment of lung cancer in Denmark, and a survey performed by 
the DLCG demonstrated major variation in the clinical mana gement. The DLCG there-
fore decided to create a set of national guidelines for the management of lung cancer in 
Denmark. The first edition was published in 1998 and the DLCG adopted a strategy to 
implement the guidelines and concurrently monitor the implementation by reporting to 
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a new registry established by the DLCR. The first patient was 
included in DLCR on January 1, 2000.
Study population
All Danish lung cancer patients are included into the registry. 
With the currently used methods for retrieving information 
about Danish lung cancer cases, the inclusion of incident 
cases since 2003 is estimated to be above 95% and the data-
base today contains data on more than 55,000 cases of lung 
cancer including cancer of the trachea. Between 2000 and 
2002, clinicians identified and reported patients to DLCR, 
but since 2003, the lung cancer patients are identified in 
the Danish National Patient Registry (DNPR),5 where the 
first occurrence of the diagnostic codes DC34 and DC33 
according to the International Classification of Diseases, 
10th Revision (ICD-10) is identified. These patients and their 
activities (procedures and treatments) form a basic database 
with information derived from the DNPR and the Danish 
Pathology Register (DPR)6 data alone. Subsequently, the basic 
database is used as a source for building the final qualified 
database (DLCR), which is on variable level validated and 
supplemented online by clinicians. All departments involved 
in the diagnosis and treatment of lung cancer in Denmark 
participate in DLCR and are responsible for the validation and 
supplementation of data. Since the participation is mandatory 
by law, data completeness is very high (more than 90%). Data 
on comorbidity is obtained from the DNPR.
Main variables
The database today contains information on patient charac-
teristics such as age, sex, diagnostic procedures, histology, 
tumor stage, lung function, performance, comorbidities, type 
of surgery, and/or oncological treatment and complications 
registered. Information on vital status for each patient is 
retrieved from the Danish Civil Registration System.7 Age 
at time of diagnosis and sex are inferred from the personal 
identification number (PIN), a unique system identifying age 
and sex of all Danish citizens. Since November 2013, DLCR 
also has Patient-Reported Outcome Measures (PROMs), 
the first year after treatment has finalized. PROMs are 
evidence of patient-experienced health status, and are be 
applied to evaluate the experiences and needs of the lung 
cancer patients. Monitoring symptoms, functional capacity, 
and quality of life have the potential to improve quality and 
the result of treatment effort. The European Organization 
for Research and Treatment of Cancer (EORTC) 30 and 
EORTC-LC13 are used as questionnaire.8,9
The recorded diagnostic procedures are the procedures 
performed in cases suspected of lung cancer to diagnose 
the disease and the type of lung cancer, and to conclude on 
treatment options based on these informations and the stag-
ing of the lung cancer, lung function, the performance of 
the patient, and relevant comorbidities. DLCR also provide 
data concerning delays in the diagnostic evaluation and treat-
ment. For the classification of comorbidity, the Charlson’s 
comorbidity index10 is used.
Details on surgical treatment are recorded including dates, 
type of surgery, and complications. Information on primary 
oncological treatment includes the amount and type of radia-
tion therapy, and the type and duration of chemotherapy.
Follow-up
After the primary treatments are finalized, all patients are 
offered to enter a follow-up program consisting of clinical 
 controls and computed tomography scans in fixed intervals. 
The contents of and time spacing between the follow-up 
visits are according to national guidelines on follow-up of 
lung  cancer, and these procedures together with informa-
tion on treatment of recurrence are registered in the DLCR. 
The patient’s vital status is updated in the database once a 
month.
Examples of research
The first peer-reviewed articles based on the data in DLCR 
were published in 2009 and since an increasing number of 
papers have been published yearly. Publications based on the 
DLCR are yearly listed in the annual report.11
A number of papers have focused on documenting the 
effects of a national clinical database such as the DLCR. 
Thus, Jakobsen et al12 in 2013 published a work entitled 
“Nationwide quality improvement in lung cancer care: the 
Danish Lung Cancer Registry,” in which they conclude “that 
a comprehensive national quality management system includ-
ing national guidelines, a database with high data quality 
and completeness, frequent reports to the professionals and 
the public, audit and commitment from all stakeholders can 
contribute to improve practice and results and reduce regional 
differences.” Table 1 shows the quality indicators used in 
DLCR in 2013. These indicators are continuously being 
evaluated and revised. Figure 1 is an example on how the 
indicators are reported in the annual reports. This indicator 
shows the degree of accordance between the clinical stage 
of the lung cancer and postoperative stage and is one of the 
most important quality indicators of the diagnostic set up. 
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Table 1 The quality indicators used in DLCR in 2014
Indicator  
group
Number Indicator Type Threshold 
 (%)
Time reference Prognostic  
factors
Adjustments
I. Survival,  
overall
ia Proportion of patients,  
surviving 1 year from  
date of diagnosis
Outcome 42 Date of diagnosis Clinical stage 
Histology 
Region 
Year of diagnosis 
Operation (yes/no) 
Comorbidity
Age 
Sex
ib Proportion of patients,  
surviving 2 years from  
date of diagnosis
Outcome 22
 ic Proportion of patients,  
surviving 5 years from  
date of diagnosis
Outcome 12
II. Survival,  
after surgery
iia Proportion of patients,  
surviving 30 days from  
date of operation
Outcome 97 Date of operation Clinical stage 
Type of operation 
Region 
Year of operation 
Comorbidity
Age 
Sex
iib Proportion of patients,  
surviving 1 year from  
date of operation
Outcome 75
 iic Proportion of patients,  
surviving 2 years from  
date of operation
Outcome 65
iid Proportion of patients,  
surviving 5 years from  
date of operation
Outcome 40
III. Waiting  
times
iiia Proportion of patients 
operated within  
42 days after referral
Structural 85 Date of operation Year of treatment 
Department 
Region
Age 
Sex
iiib Proportion of patients  
starting oncologic  
treatment within  
42 days after referral
Structural 85 Date of first  
oncologic  
treatment
iiic Proportion of patients  
starting chemotherapy  
within 42 days after  
referral
Structural 85 Date of first  
chemotherapy
iiid Proportion of patients  
starting radiotherapy  
within 42 days after  
referral
Structural 85 Date of first  
radiotherapy
 iiie Proportion of patients  
starting chemotherapy  
and radiotherapy  
within 42 days after  
referral
Structural 85 Date of first  
chemotherapy  
and radiotherapy
IV. Stage 
classification
iv Proportion of patients  
with accordance  
between cTNM and  
pTNM
Process 85 Date of operation Department 
Region 
Year of operation
Age 
Sex
V. Resection  
rate
v Proportion of patients  
with NSCLC who had  
a resection
Process 20 Date of operation Region 
Year of diagnose 
Comorbidity
Age 
Sex
Abbreviations: DLCR, Danish Lung Cancer Registry; cTNM, clinical stage of the lung cancer; NSCLC, non-small-cell lung cancer; TNM, tumor node metastasis; 
pTNM, postoperative stage.
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The higher accordance, the better quality of the diagnostic 
set up and the higher the probability of the patient receiving 
the optimal treatment. The indicator shows the different result 
in the five Danish regions.
The research based on the data in DLCR furthermore has 
focused on two main topics, comorbidity and inequality. In 
four consecutive articles, the importance of comorbidity in 
lung cancer treatment and survival has been evaluated.13–16 
Socioeconomic position and different aspects of lung can-
cer have been explored in another series of papers with the 
overall conclusion that socioeconomic position is a major 
prognostic factor in lung cancer survival and treatment.17–19 
These and other publications document the growing impor-
tance of national and international cooperation in lung cancer 
research.
Administrative issues and funding
DLCR is one of the national supported databases organized 
under the administration of the Joint Secretariat for the 
 Danish Clinical Quality Improvement Program (Databasernes 
Fælles-sekretariat, Regionernes Kliniske  Kvalitetsudviklings 
program, RKKP). Furthermore, the DLCG is a part of the 
Danish Multidisciplinary Cancer Groups (DMCG.dk), 
a national network of physicians and other health care pro-
fessionals, scientists, and government officials committed 
to improving cancer care in Denmark. Funding is through 
the Danish Clinical Quality Improvement Program. Data in 
the clinical databases connected to RKKP including DLCR 
are on application to the organizations available for all 
 Danish researchers.
Conclusion
DLCR contains information on every incident primary case 
of lung cancer in Denmark since 2003. The variables include 
patient age, sex, diagnostic procedures, histology, tumor 
stage, lung function, performance, comorbidities, type of 
surgery, and/or oncological treatment, complications regis-
tered, and the patient’s vital status. Since November 2013, 
DLCR also have included PROMs the first year after treat-
ment has been finalized. DLCR has, since its creation, been 
used to improve the quality of treatment of lung cancer in 
Denmark and it is increasingly used as a source for research 
regarding lung cancer in Denmark and in comparisons with 
other countries.
Acknowledgments
DLCR is managed in close collaboration with Competence 
Centre South for National Clinical Databases at Odense 
 University Hospital. This article is part of the Thematic Series 
Clinical Databases in Denmark initiated by the Program for 
Clinical Research Infrastructure (PROCRIN).
Disclosure
The authors report no conflicts of interest in this work.
References
1. Tulinius H, Storm HH, Pukkala E, Andersen A, Ericsson J. Cancer in 
the Nordic countries, 1981–86. A joint publication of the five Nordic 
Cancer Registries. Acta Pathol Microbiol Immunol Scand. 1992;100(31): 
1–94.
2. Hansen J, Olsen JH. Survival of Danish cancer patients 1943–1987. 
Respiratory system. APMIS Suppl. 1993;33:77–98.
100%
90%
80%
70%
60%
50%
2003 2004 2005 2006 2007 2008
Year
2009 2010 2011 2012
Figure 1 Time trends in the accordance between cTNM and pTNM across health care region.
Abbreviations: cTNM, clinical stage of the lung cancer; TNM, tumor node metastasis; pTNM, postoperative stage.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
03
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-epidemiology-journal
Clinical Epidemiology is an international, peer-reviewed, open access, 
online journal focusing on disease and drug epidemiology, identifica-
tion of risk factors and screening procedures to develop optimal pre-
ventative initiatives and programs. Specific topics include: diagnosis, 
prognosis, treatment, screening, prevention, risk factor modification, 
systematic reviews, risk & safety of medical interventions, epidemiol-
ogy & biostatistical methods, and evaluation of guidelines, translational 
medicine, health policies & economic evaluations. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system, which is all easy to use.
Clinical epidemiology 2016:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
541
Danish Lung Cancer Registry
 3. Andersen KB. Lung cancer—better prognosis? Ugeskr Laeger. 
1994;156(33):4719–4720.
 4. Engeland A, Bjorge T, Haldorsen T, Tretli S. Prognosis of patients with 
lung cancer diagnosed in Norway, 1954–93. Cancer Causes Control. 
1998;9:57–65.
 5. Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. 
Scand J Public Health. 2011;39(7 Suppl):30–33.
 6. Bjerregaard B, Larsen OB. The Danish pathology register. Scand J 
Public Health. 2011;39(7 Suppl):72–74.
 7. Pedersen CB. The Danish civil registration system. Scand J Public 
Health. 2011;39(7 Suppl):22–25.
 8. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organi-
zation for Research and Treatment of Cancer QLQ-C30: a quality-of-
life instrument for use in international clinical trials in oncology. J Natl 
Cancer Inst. 1993;85(5):365–376.
 9. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The 
EORTC QLQ-LC13: a modular supplement to the EORTC Core 
Quality of Life Questionnaire (QLQ-C30) for use in lung cancer 
clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 
1994;30A(5):635–642.
 10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of 
classifying prognostic comorbidity in longitudinal studies: development 
and validation. J Chronic Dis. 1987;40:373–383.
 11. Årsrapport 2014 Dansk Lunge Cancer Register (Danish). Available 
from: http://lungecancer.dk/documents/ED76D14E-3915-4D9C- 
9033-55D1B03402FB.pdf. Accessed January 8, 2015.
 12. Jakobsen E, Green A, Oesterlind K, Rasmussen TR, Iachina M, 
Palshof T. Nationwide quality improvement in lung cancer care: the 
Danish Lung Cancer Registry. J Thorac Oncol. 2013;8:1238–1247.
 13. Lüchtenborg M, Jakobsen E, Krasnik M, Linklater KM,  Mellemgaard A, 
Møller H. The effect of comorbidity on stage-specific survival in 
resected non-small cell lung cancer patients. Eur J Cancer. 2012; 
48(18):3386–3395.
 14. Iachina M, Green A, Jakobsen E. The direct and indirect impact of 
comorbidity on the survival of patients with non-small cell lung cancer: 
a combination of survival, staging and resection models with missing 
measurements in covariates. BMJ Open. 2014;4:e003846.
 15. Mellemgaard A, Lüchtenborg M, Lachina M, et al. Role of comorbidity 
on survival after radio- and chemotherapy for non-surgically treated 
lung cancer. J Thorac Oncol. 2015;10(2):272–279.
 16. Iachina M, Jakobsen E, Møller H, et al. The effect of different comor-
bidities on survival of non-small cells lung cancer patients. Lung. 
2015;193:291–297.
 17. Dalton S, Frederiksen B, Jacobsen E, et al. Socioeconomic posi-
tion, stage of lung cancer and time between referral and diagnosis in 
 Denmark, 2001–2008. Br J Cancer. 2011;105:1045–1048.
 18. Kærgaard Starr L, Osler M, Steding-Jessen M, et al. Socioeconomic 
position and surgery for early-stage non small cell lung cancer: 
a  population-based study in Denmark. Lung Cancer. 2013;79: 
262–269.
 19. Dalton S, Steding-Jessen M, Jakobsen E, et al. Socioeconomic position 
and survival after lung cancer – the influence of stage, treatment and 
comorbidity among Danish lung cancer patients diagnosed 2004–2010. 
Acta Oncol. 2015;54(5):797–804.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
03
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
